Is there a relationship between gliflozins and acute pancreatitis? Evidence-based analysis
DOI:
https://doi.org/10.56294/dm202277Keywords:
Sodium-Glucose Transporter 2 Inhibitors, Pancreatitis, Diabetes Mellitus Type 2, Evidence-Based DecisionsAbstract
Background: acute pancreatitis is a sudden inflammation of the pancreas with the possibility of presenting severe complications. Diabetes is a chronic metabolic disease, the cause of a large part of global morbidity and mortality. Approximately 90 % of patients with diabetes suffer from type II diabetes. Several studies were carried out in this regard, and with fairly large samples in quantitative terms. Within the treatment of type II diabetes there are hypoglycemic agents, of which there is a group called gliflozins or also inhibitors of sodium-glucose cotransporter 2 (SGLT2is) such as canagliflozin and empagliflozin.
Methods: a systematic review of the literature available in databases such as PubMed was carried out, carrying out specific investigations to identify case reports of acute pancreatitis associated with the use of gliflozin. For this, an exhaustive reading of all the available articles was carried out.
Results: of the 4 articles analyzed, the average incidence of pancreatitis in patients who used gliflozin was 0,38 %.
Conclusion: we conclude that it is not possible to establish a causal relationship between the use of gliflozin and acute pancreatitis
References
1. Tang H, Yang K, Li X, Song Y, Han J. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2020 Feb;29(2):161-172. https://doi.org/10.1002/pds.4943. PMID: 32017292.
2. Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Mol Basel Switz 2020;25:1987.
3. Yuan Z, DeFalco F, Wang L, Hester L, Weaver J, Swerdel JN, Freedman A, Ryan P, Schuemie M, Qiu R, Yee J, Meininger G, Berlin JA, Rosenthal N. Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Curr Med Res Opin. 2020 Jul;36(7):1117-1124. https://doi.org/10.1080/03007995.2020.1761312. Epub 2020 May 14. PMID: 32338068.
4. Wang YW, Lin JH, Yang CS. Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine (Baltimore). 2022 Aug 26;101(34):e30072. https://doi.org/10.1097/MD.0000000000030072.
5. Hoogwerf BJ. Type of diabetes mellitus: Does it matter to the clinician? Cleve Clin J Med 2020;87:100-8.
6. Kmietowicz Z. SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputation. BMJ. 2018 Nov 14;363:k4828. https://doi.org/10.1136/bmj.k4828.
7. Neal B, Perkovic V, Mahaffey KW, et al, CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-57. https://doi.org/10.1056/ NEJMoa1611925
8. Porcile R, Perez Baztatrrica G, Escobar LA, Levin R, Botbol A. Acute Myocardial infarction in patients under 45 years old. Interamerican Journal of Health Sciences. 2021;(1). https://doi.org/10.59471/ijhsc20219
9. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2016;101:157-66. https://doi.org/10.1210/jc.2015-3167
10. Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018 Nov 14;363:k4365. https://doi.org/10.1136/bmj.k4365.
11. Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 2018;20:620-8. https://doi.org/10.1111/dom.13124
12. Antza C, Kostopoulos G, Mostafa S, Nirantharakumar K, Tahrani A. The links between sleep duration, obesity and type 2 diabetes mellitus. J Endocrinol 2021;252:125-41. https://doi.org/10.1530/JOE-21-0155.
13. Barreiro RB, Grzona E. Factors associated with Irritable Bowel Syndrome in medical students. Interamerican Journal of Health Sciences. 2021;(1). https://doi.org/10.59471/ijhsc202115
14. Kohler S, Zeller C, Iliev H, Kaspers S. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Adv Ther 2017;34:1707-26. https://doi.org/10.1007/ s12325-017-0573-0
15. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. J Clin Endocrinol Metab 2016;101:44-51. https://doi.org/10.1210/jc.2015-1860
16. Arra A, Coso D, Chagas Guimaraes L. SATB.2 is a sensityive for well differentiated neuroendocrine tumors. Interamerican Journal of Health Sciences. 2021;(1). https://doi.org/10.59471/ijhsc20214
17. Chen L, Klein T, Leung PS. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med. 2012 Sep;12(8):995-1004. https://doi.org/10.2174/156652412802480970.
18. Patel KM, Pikas E, George T. Drug-Induced Necrotizing Pancreatitis With a Focus on Canagliflozin. Am J Ther. 2017 Jul/Aug;24(4):e496. https://doi.org/10.1097/MJT.0000000000000561.
19. Chibas-Muñoz EE, Sarabia Aguila EC, Quintero Alvarez PE, Landrove-Escalona E, Creagh Bandera R. Factores epidemiológicos que influyen en la estadía hospitalaria de pacientes con diagnóstico de Diabetes Mellitus. Salud, Ciencia y Tecnología - Serie de Conferencias. 2022;1(1):7. https://doi.org/10.56294/sctconf20227
20. Burillo J, Marqués P, Jiménez B, González-Blanco C, Benito M, Guillén C. Insulin Resistance and Diabetes Mellitus in Alzheimer’s Disease. Cells 2021;10:1236. https://doi.org/10.3390/cells10051236.
21. Flores Siranaula GM, Clavijo Rosales CG, Taimal Sarez CM. Rol de la vitamina D en pacientes con diabetes mellitus tipo 2. Salud, Ciencia y Tecnología. 2022;2:202. https://doi.org/10.56294/saludcyt2022202
22. Damanik J, Yunir E. Type 2 Diabetes Mellitus and Cognitive Impairment. Acta Medica Indones 2021;53:213-20
Published
Issue
Section
License
Copyright (c) 2022 Marina Stopa Couto, Marcelo Adrián Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
